This is a routine director-level Form 144 for a small position relative to market cap. The sale is tied to option exercise, not a conviction sell-down. Monitor for actual execution on Form 4, but no immediate trading action is warranted.
Price Chart
Executive Summary
Director Raymond Anderson filed a Form 144 notice of intent to sell 6,284 shares of Monopar Therapeutics common stock, with an estimated aggregate market value of approximately $699,786. The shares are to be acquired upon exercise of stock options. This is a relatively small sale relative to the company's $747M market cap and appears to be a routine option exercise and sale by a director, not a CEO/CFO, limiting its signaling value.
Key Facts
- Director Raymond Anderson filed Form 144 to sell 6,284 shares of Monopar Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is approximately $699,786.
- The shares are to be acquired upon exercise of stock options.
- The filing date is August 25, 2026.
- The sale is intended to be executed through Morgan Stanley Smith Barney LLC.
Financial Impact
Proposed sale of 6,284 shares valued at approximately $699,786, representing about 0.09% of the company's $747M market cap.
Risk Factors
- The sale may signal the insider's desire to diversify or raise cash, though the small size limits concern.
- If additional insiders file similar notices in the near term, it could indicate a broader selling pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-008691 |
| Document: 0001950047-26-008691-index.html | 0001950047-26-008691 |
| Document: 0001950047-26-008691.txt | 0001950047-26-008691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers